Tables and Figures

Exhibit 5.1 Respondents’ Subject Matter Category in Microbiome R&D
 
 
Exhibit 5.2 Type of Organization Where Respondents Work
 
 
Exhibit 5.3 Further description of type of company where respondents work
 
 
Exhibit 5.4 Respondents’ Position/Designation at the Workplace
 
 
Exhibit 5.5 Type of Work Currently Performed by Respondents
 
 
Exhibit 5.6 Type of Work Respondents Will Likely Perform in the Next Year
 
 
Exhibit 5.7 Respondents’ Current Research Focus by Body Site/Niche
 
 
Exhibit 5.8 Respondents’ Current Research Focus by Therapeutic Areas
 
 
Exhibit 5.9 Respondents’ Current Research Focus by Disease Condition
 
 
Exhibit 5.10 Respondents’ Current or Future Research Focus by Product
 
 
Exhibit 5.11 Respondents’ Expectation of Change in Their Organization’s Microbiome Involvement in the Next Two Years
 
 
Exhibit 5.12 Respondents’ Opinion Regarding Academic Participation in Developing New Concepts for Rx and/or Dx of Dysbiosis
 
 
Exhibit 5.13 Respondents’ Level Agreement with Statement: Current Methods are Adequate for Quantitative Characterization
 
of the Microbiome for Personalized Medicine
 
 
Exhibit 5.14 Respondents’ Level Agreement with Statement: Sufficient Information about the Composition and Function of
 
Human Microbiomes has been Gathered to Justify Translational R&D
 
 
Exhibit 5.15 Respondents’ Current Research Work on Detecting Dysbiosis Uses the Following Techniques
 
 
Exhibit 5.16 Respondents’ Opinion on the Potential of Microbiome R&D to Provide Major Contributions to Healthcare
 
 
Exhibit 5.17 Respondents’ Level of Agreement with the Statement: "Recent Findings Relating the Microbiome to Health and Disease
 
Will Enable an Important New Generation of Therapies for a Number of Chronic Diseases.”
 
 
Exhibit 5.18 Respondents’ Level of Agreement With the Statement: "Recent Findings Relating the Microbiome to Health and Disease
 
Will Provide an Important New Generation of Measures to Maintain Good Health."
 
 
Exhibit 5.19 Respondents’ Level of Agreement With the Statement: "It is Still Early Days for Translational Interventions Based on
 
Microbiome R&D, and More Years of Research are Necessary to Establish its Potential."
 
 
Exhibit 5.20 Respondents’ Level of Agreement With the Statement: "Sequencing Technologies Will Remain Dominant Over Microarrays
 
for Most Microbiome Diagnostic Applications."
 
 
Exhibit 5.21 Respondents’ Level of Agreement With the Statement: "Big Pharma Involvement in Microbiome-related R&D Will Increase
 
Significantly Over the Next Decade.”
 
 
Exhibit 5.22 Respondents’ Level of Agreement With the Statement: "We Can Expect a Flood of New Rationally Designed and/or
 
Personalized Biotherapeutics to Emerge During the Next Decade."